New drug combo to save the bladder in HER2-positive bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests combining two newer drugs (zanidatamab and tislelizumab) with standard chemotherapy before bladder surgery. The goal is to shrink the tumor so the bladder can be saved instead of removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have bladder cancer that has not spread beyond the pelvis and has at least a moderate level of HER2 protein (IHC 2+ or 3+).
- You have not had prior treatment with drugs targeting HER2 or immune checkpoint inhibitors (like Keytruda, Opdivo).
- You have not had radiation therapy to the bladder for bladder cancer.
- Your overall health allows for daily activity (ECOG 0-2) and your organ function (kidney, liver, blood counts) is adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, trastuzumab rezetecan and adebrelimab, given before surgery for a type of bladder cancer that has grown into the muscle. The goal is to see if this combination can shrink the tumor and improve outcomes for patients whose cancer cells have a certain protein called HER2.
This trial tests a combination of two drugs (trastuzumab rezetecan and adebrelimab) plus radiation to the bladder, aiming to preserve the bladder instead of removing it. It's for people with muscle-invasive bladder cancer that shows a specific marker called HER2.
This trial tests whether giving a combination of two drugs before and after surgery can help people with HER2-positive bladder cancer that has grown into the bladder muscle. The goal is to see if this approach can shrink or control the cancer before the bladder is removed.
This trial tests a combination of two drugs—vedisertib (RC48) and toripalimab—for people with bladder cancer that has invaded the muscle but hasn't spread. The goal is to preserve the bladder while treating the cancer.
This trial tests a combination of two drugs (disitamab vedotin and tislelizumab) given before a second bladder surgery (re-TURBT) for people with high-risk non-muscle invasive bladder cancer that has high HER2 levels. The goal is to see if this approach improves outcomes compared to standard care.
This study tests a combination of a targeted drug (disitamab vedotin), an immunotherapy drug (PD-1 inhibitor), and radiation therapy as a way to treat bladder cancer without removing the bladder. It is for people whose cancer has grown into the bladder muscle but hasn't spread to other parts of the body, and whose tumor shows high HER2 levels.
Hear when a new Muscle Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.